Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.

Filiaciones

Pros E:

Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

Saigi M:

Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain

Alameda D:

Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra and Navarra Health Research Institute (IDISNA), Pamplona, Spain

Gomez-Mariano G:

Molecular Genetics Unit, Rare Diseases Institute of Research (IIER), Health Institute Carlos III, Majadahonda, Madrid, Spain

Martinez-Delgado B:

Molecular Genetics Unit, Rare Diseases Institute of Research (IIER), Health Institute Carlos III, Majadahonda, Madrid, Spain

Alburquerque-Bejar JJ:

Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

Carretero J:

Department of Physiology, Faculty of Medicine and Odontology, University of Valencia, Valencia, Spain

Tonda R:

CNAG-CRG, Centre for Genomic Regulation (CRG), Institute of Science and Technology (BIST) and University Pompeu Fabra (UPF), Barcelona, Spain

Esteve-Codina A:

CNAG-CRG, Centre for Genomic Regulation (CRG), Institute of Science and Technology (BIST) and University Pompeu Fabra (UPF), Barcelona, Spain

Catala I:

Pathology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Spain

Palmero R:

Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain

Jove M:

Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain

Lazaro C:

Hereditary Cancer Program, Catalan Institute of Oncology, ICO-Oncobell-IDIBELL, Madrid, Spain

CIBERONC, Health Institute Carlos III, Madrid, Spain

Patiño-Garcia A:

Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra and Navarra Health Research Institute (IDISNA), Pamplona, Spain

Gil-Bazo I:

Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra and Navarra Health Research Institute (IDISNA), Pamplona, Spain

CIBERONC, Health Institute Carlos III, Madrid, Spain

Verdura S:

Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

Teulé A:

Hereditary Cancer Program, Catalan Institute of Oncology, ICO-Oncobell-IDIBELL, Madrid, Spain

CIBERONC, Health Institute Carlos III, Madrid, Spain

Torres-Lanzas J:

Thoracic Surgery Department, Hospital Universitario Virgen de la Arrixaca, El Palmar-Murcia, Spain

Sidransky D:

Department of Otolaryngology and Head and Neck Surgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland

Reguart N:

Oncology Department, Thoracic Tumors Unit, Clinic Hospital, Barcelona, Spain

Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain

Pio R:

Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra and Navarra Health Research Institute (IDISNA), Pamplona, Spain

CIBERONC, Health Institute Carlos III, Madrid, Spain

Juan-Vidal O:

Instituto de Investigación. Biomarkers and Precision Medicine Unit, Research Institute La Fe and Department of Medical Oncology, La Fe University Hospital, Valencia, Spain

Nadal E:

Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain

Clinical Research in Solid Tumors Group (CReST), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Spain

Felip E:

Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain

Montuenga LM:

Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra and Navarra Health Research Institute (IDISNA), Pamplona, Spain

CIBERONC, Health Institute Carlos III, Madrid, Spain

Department of Pathology, Anatomy and Physiology, Schools of Medicine and Sciences, University of Navarra, Pamplona, Spain

Sanchez-Cespedes M:

Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain